title: [Analysis on drug resistance of Mycobacterium tuberculosis and influencing factors in six provinces of China].
abstract: OBJECTIVE
  To analyze the drug-resistance of clinical Mycobacterium tuberculosis strains isolated from the tuberculosis(TB)patients in six provinces in China and related risk factors, and provide evidences for the effective prevention and treatment of drug resistant TB.
  
  
  METHODS
  Six provinces were selected from China. The background information of the TB patients was investigated with questionnaire survey, and the drug susceptibilities of the clinical M. tuberculosis strains to isoniazid, rifampin, ethambutol and streptomycin were tested by means of the proportional drug susceptibility test. Then the results and related risk factors were analyzed with software SPSS 20.0.
  
  
  RESULTS
  The overall drug resistant rate and multi drug-resistant(MDR)rate were 23.42% and 13.51% respectively. The overall drug resistant rate and MDR rate in Beijing, Jilin, Hunan, Henan, Shaanxi, Xinjiang were 21.50%, 12.24%, 36.27%, 42.86%, 27.78%, 24.39% and 4.67%, 8.16%, 24.51%, 26.53%, 15.28%, 14.15%, respectively. The χ(2) analysis results showed that the differences in single drug-resistant rate, overall drug resistant rate and MDR rate in these provinces had significant differences(P=0.000). The univariate statistical analysis results showed that the retreatment for TB and TB treatment history were the risk factors associated with drug resistance(P<0.05).
  
  
  CONCLUSIONS
  The drug resistance of TB was very serious in China, but the TB drug resistance varied with province. The preventive intervention should be strengthened against all the major risk factors associated with the drug resistance for the better prevention and control of TB.
authors.affiliation: Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China; State Key Laboratory of Communicable Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Song
authors.affiliation: Department of Physiology, Xiangya Medical School, Central South University, Changsha 410000, China; State Key Laboratory of Communicable Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
authors.forename: L
authors.initials: L
authors.lastname: Wan
authors.affiliation: State Key Laboratory of Communicable Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China; Institute of Pathogenic Biology, University of South China, Hengyang 421000, China.
authors.forename: S S
authors.initials: SS
authors.lastname: Chen
authors.affiliation: State Key Laboratory of Communicable Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China; Institute of Pathogenic Biology, University of South China, Hengyang 421000, China.
authors.forename: Y J
authors.initials: YJ
authors.lastname: Xu
authors.affiliation: State Key Laboratory of Communicable Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
authors.forename: Z G
authors.initials: ZG
authors.lastname: Liu
authors.affiliation: State Key Laboratory of Communicable Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
authors.forename: X Q
authors.initials: XQ
authors.lastname: Zhao
authors.affiliation: State Key Laboratory of Communicable Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
authors.forename: H C
authors.initials: HC
authors.lastname: Liu
authors.affiliation: Institute of Pathogenic Biology, University of South China, Hengyang 421000, China.
authors.forename: Y M
authors.initials: YM
authors.lastname: Wu
authors.affiliation: State Key Laboratory of Communicable Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China; Institute of Pathogenic Biology, University of South China, Hengyang 421000, China.
authors.forename: K L
authors.initials: KL
authors.lastname: Wan
authors.affiliation: Department of Physiology, Xiangya Medical School, Central South University, Changsha 410000, China.
authors.forename: C X
authors.initials: CX
authors.lastname: Guan
authors.affiliation: Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China.
authors.forename: M
authors.initials: M
authors.lastname: Liu
mesh_terms: D000995:Antitubercular Agents / Q000494:pharmacology*; D002681:China / Q000453:epidemiology; D024901:Drug Resistance, Multiple, Bacterial; D004977:Ethambutol / Q000494:pharmacology; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000302:isolation & purification*; D015995:Prevalence; D012293:Rifampin / Q000627:therapeutic use; D012307:Risk Factors; D013307:Streptomycin / Q000494:pharmacology; D011795:Surveys and Questionnaires; D018088:Tuberculosis, Multidrug-Resistant / Q000453:epidemiology* / Q000382:microbiology
chemical_list: D000995:Antitubercular Agents; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin